Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 2035-2040

  Kim, Joo Hyun ^a   Kim, Won Seog ^a   Park, Chaehwa ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

AID; B cell lymphoma; EBV; Egr 1; LMP1; Rassf6

Indexed keywords

CYTIDINE DEAMINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA; PROTEIN P53; PROTEIN RASSF 6; TRANSCRIPTION FACTOR EGR 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BINDING SITE; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENOMIC INSTABILITY; GERMINAL CENTER; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; WILD TYPE;

CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CYTIDINE DEAMINASE; DNA COPY NUMBER VARIATIONS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENOMIC INSTABILITY; HUMANS; LYMPHOMA, B-CELL; MONOMERIC GTP-BINDING PROTEINS; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; UP-REGULATION; VIRAL MATRIX PROTEINS;

EID: 84883043409     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.769218     Document Type: Article

References (40)

1. Fhraeus R, Fu H L, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-338.
2. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin ' s disease. N Engl J Med 1989;320:502-506.
3. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769-774.
4. Kwon JM, Park YH, Kang JH, et al. The eff ect of Epstein-Barr virus status on clinical outcome in Hodgkin ' s lymphoma. Ann Hematol 2006;85:463-468.
5. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diff use large B-cell lymphoma. Blood 2007;110:972-978.
6. Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin' s disease. J Pathol 1992;166:1-5.
7. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-1782.
8. Huen D S, Henderson S A, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two eff ector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-560.
9. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131-6140.
10. Mcfarland EDC, Izumi KM, Mosialos G. Epstein-Barr virus transformation involvement of latent membrane protein 1-mediated activation of NFkB. Oncogene 1999;19:6959-6964.
11. Baumforth KR, Young LS, Flavell KJ, et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307-322.
12. Kim JH, Kim WS, Kang JH, et al. Egr-1, anew downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Lett 2007;581:623-628.
13. Kim JH, Kim WS, Park C. SNARK, anovel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. Leuk Lymphoma 2008;49:1392-1398.
14. He B, Raab-Traub N, Casali P, et al. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cellindependent Ig heavy chain class switching. J Immunol 2003;171:5215-5224.
15. de Ybenes VG, Ramiro AR. Activation-induced deaminase: Light and dark sides. Trends Mol Med 2006;12:432-439.
16. Longerich S, Basu U, Alt F, Storb U. AID in somatic hypermutation and class switch recombination. Curr Opin Immunol 2006;18:164-174.
17. Delker RK, Fugmann SD, Papavasiliou FN. A coming-of-age story:Activation-induced cytidine deaminase turns 10. Nat Immunol 2009;10:1147-1153.
18. Kuraoka M, McWilliams L, Kelsoe G. AID expression during B-cell development: Searching for answers. Immunol Res 2011;49:3-13.
19. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diff use large-cell lymphomas. Nature 2001;412:341-346.
20. Iacobucci I, Lonetti A, Messa F, et al. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia 2010;24:66-73.
21. Nagaoka H, Tran TH, Kobayashi M, et al. Preventing AID, aphysiological mutator, from deleterious activation: Regulation of the genomic instability that is associated with antibody diversity. Int Immunol 2010;22:227-235.
22. Park SR, Zan H, Pal Z, et al. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. Nat Immunol 2009;10:540-550.
23. Allen NP, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007;26:6203-6211.
24. Epeldegui M, Hung YP, McQuay A, et al. Infection of human B cells wiThepstein-Barr virus results in the expression of somatic hypermutation- inducing molecules and in the accrual of oncogene mutations. Mol Immunol 2007;44:934-942.
25. Gonda H, Sugai M, Nambu Y, et al. The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med 2003;198:1427-1437.
26. Dedeoglu F, Horwitz B, Chaudhuri J, et al. Induction of activationinduced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int Immunol 2004;16:395-404.
27. Yadav A, Olaru A, Saltis M, et al. Identification of a ubiquitously active promoter of the murine activation-induced cytidine deaminase (AICDA) gene. Mol Immunol 2006;43:529-541.
28. Ikeda M, Hirabayashi S, Fujiwara N, et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 2007;313:1484-1495.
29. Hasham MG, Donghia NM, Coff ey E, et al. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol 2010;11:820-826.
30. Matsumoto Y, Marusawa H, Kinoshita K, et al. Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer. Gastroenterology 2010;139:1984-1994.
31. Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell 2009;36:631-641.
32. Lawler J, Detmar M. Tumor progression :The eff ects of thrombospondin-1 and-2. Int J Biochem Cell Biol 2004;36:1038-1045.
33. Chiliwa T, Abe Y, Ikoma N, et al. Th romobospondin 2 inhibits metastasis of human malignant melanoma through microenvironment modification in NOD/SCID/gamaCnull (NOG) mice. Int J Oncol 2009;34:5-13.
34. Ftterer A, Campanero MR, Leonardo E, et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 2005;115:2351-2362.
35. Garca-Domingo D, Leonardo E, Grandien A, et al. DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci USA 1999;96:7992-7997.
36. Wu H, Ma Y, Zhu Y, et al. Expression of BIRC7 protein and mRNA in non-Hodgkin' s lymphoma. Leuk Lymphoma 2006;47:1110-1116.
37. Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 2011;11:633-649.
38. Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 2000;160:89-97.
39. Ho C H, Hsu C F, Fong P F, et al. Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. Virology 2007;81:4837-4847.
40. Chang P M, Chen P M, Hsieh S L, et al. Expression of a soluble decoy receptor 3 in patients with diff use large B-cell lymphoma predicts clinical outcome. Int J Oncol 2008;33:549-554.